Paradigm Biopharmaceuticals Ltd. · ASX:PAR
Paradigm Biopharmaceuticals — Investor Presentation (March 2016)
21 slides from Paradigm Biopharmaceuticals's investor presentation, Mar 16, 2016
Slide 1: Shareholder Update ASX Release
ASX RELEASE SHAREHOLDER UPDATE For personal use only 16 March 2016, Melbourne, Australia: Paradigm Biopharmaceuticals Limited (ASX: PAR) is an Australian Biopharmaceutical company focused on repurposing Pentosan Polysulfate Sodium (PPS) as a potential new treatment for Bone Marrow Edema (BME) and re
Slide 2: Investor presentation
For personal use only Investor presentation Paul Rennie, CEO 16 March 2016
Slide 3: Company highlights
Company highlights For personal use only Repurposing a pre-approved drug to reduce clinical costs and accelerate commercialisation Pentosan Polysulfate Sodium is a new, multi-acting treatment for bone marrow edema and allergic rhinitis, both of which have very large addressable markets (US$13.5b
Slide 4: Company overview
Company overview For personal use only Financial information Top shareholders2,3 Shares (m) % Share price (14-Mar-16) A$0.31 Paul Rennie (Managing Director) 21.2 24.2% Number of shares1 87.6m MJGD Nominees (Xosoma vendor) 7.1 8.1% Market capitalisation A$27.2m Other Board and management 7.1 8.1% Cas
Slide 5: Operational milestones
Operational milestones For personal use only Paradigm has met all short term deliverables since IPO Initial public offering BME clinical trial approved Respiratory patent Paradigm lists on Ethics approval Secured European the ASX raising granted from the patent to use PPS to A$8.0m at A$0.35 H
Slide 6: Board and management
Board and management For personal use only Highly quality Board and management, with top tier pharmaceutical experience Board and management are renowned leaders in the biopharmaceutical industry, having held senior management positions with top ASX-listed companies, CSL (CSL.ASX) and Mesoblast (M
Slide 7: Focus on drug repurposing
Focus on drug repurposing For personal use only Much lower cost, accelerated timeline, lower risk and with higher rates of success Lower cost: average development cost of US$8-41m compared to US$1.3bn for “de novo” development1,3 Faster: leverages the value of previous clinical efforts which acc
Slide 8: Repurposing Pentosan Polysulfate Sodium
Repurposing Pentosan Polysulfate Sodium For personal use only Biologically PPS is an ideal drug to treat the issues associated with BME and AR Existing applications Repurposed applications Deep vein thrombosis BME treatment via ZILOSUL® - refer to slides 8-11 Interstitial cystitis or painful b
Slide 9: Bone Marrow Edema (BME)
Bone Marrow Edema (BME) For personal use only Injuries related to BME are a significant burden on health care expenditure What is BME (bone bruising)? Addressable market based on acute Disorder causing excess fluid build-up inside bone, traumatic injuries: typically at the end of long bones Why fo
Slide 10: BME: Comparative advantages of ZILOSUL
BME: Comparative advantages of ZILOSUL® For personal use only Multi-acting treatment that addresses the underlying pathology of BME ZILOSUL® is the only therapy being used that addresses multiple pathways to treat BME ‒ ZILOSUL® provides a more complete solution to BME ‒ Competing treatments have
Slide 11: BME: Clinical development program
BME: Clinical development program For personal use only Opportunity to further accelerate clinical trial development timeline First patient enrolled in open label trial investigating the efficacy of ZILOSUL® in patients with a BME lesion due to a recent acute ACL injury — Open label design means t
Slide 12: Elite athlete case study
Elite athlete case study For personal use only Potential to open new market opportunities by treating chronic BME with ZILOSUL® Elite athlete in a major Australian sporting code successfully treated for a chronic orthopaedic injury by ZILOSUL® Robust results highlight the potential for market ex
Slide 13: Allergic Rhinitis (AR)
Allergic Rhinitis (AR) For personal use only AR is a common condition that is inadequately treated with quality of life impacts What is AR (hay fever)? Allergic inflammation of the nasal airways, when an Addressable market for allergic allergen is inhaled by a sensitised individual rhinitis / hay
Slide 14: AR: Comparative advantages of RHINOSUL
AR: Comparative advantages of RHINOSUL® For personal use only RHINOSUL® has the potential to fill the current gap in AR treatment options RHINOSUL® has multiple mechanisms of action making it a potentially superior treatment to existing therapies Meda (MEDA.STO, A$8.7bn market cap) manufacture t
Slide 15: AR: Clinical development program
AR: Clinical development program For personal use only Paradigm is on track with clinical development timeline and expenditure Paradigm is developing RHINOSUL®, the first intra-nasally applied PPS product to be used humans — For this new route of administration, Paradigm has conducted a bridging n
Slide 16: Valuable IP portfolio
Valuable IP portfolio For personal use only Multi-faceted IP protection increases barriers to entry for potential competitors Valuable patent portfolio Disease specific patents secured in a growing BME patent granted EU patents granted for respiratory diseases number of geographic regions incl. AR
Slide 17: Undervalued compared to peers
Undervalued compared to peers For personal use only Attractive investment given low risk development and large market opportunity Paradigm appears undervalued compared to similar stage, drug repurposing peers given its platform for successful development, secure industrial scale manufacturing and
Slide 18: Global interest in respiratory and BME
Global interest in respiratory and BME For personal use only Recent transactions highlight big pharma interest in respiratory and BME spaces Mylan’s recent takeover offer of Meda was at a 92% premium to last close, with Dymista® being RHINOSUL®’s closest comparative product AstraZeneca’s transac
Slide 19: Enhancing shareholder returns
Enhancing shareholder returns For personal use only Strong ongoing focus on prudent cash management Paradigm maintains a highly specialised and nimble team through effective outsourcing Paradigm’s focus is to use cash for clinical development rather than administration and overheads Evidenced
Slide 20: Share price catalysts
Share price catalysts For personal use only Focused effort on compressing the BME and AR clinical development timelines BME TRIAL Open label trial anticipated to confirm efficacy together with optimal Phase II(a) trial dosing of ZILOSUL® and clinical endpoints Potential to bring forward closed l
Slide 21: Disclaimer
Disclaimer For personal use only This document, together with any information communicated by Paradigm BioPharmaceuticals Ltd (known as “Paradigm”, “Paradigm Biopharma” or “the Company”), in any presentation or discussion relating to this document (collectively, “Information”) is confidential, and h
Paradigm Biopharmaceuticals — Investor Presentation (March 2016) on 6ix